BioNTech acquires antibody generation unit of MAB Discovery

BioNTech acquires antibody generation unit of MAB Discovery

BioNTech announced today that it entered into an agreement with MAB Discovery for the acquisition of MAB's monoclonal antibody (mAb) generation unit. The acquisition will expand BioNTech's trageting ligand repertoire and enable the direct, rapid and efficient production of new mAb candidates.

For more information, please go to www.biontech.de or see the press release in the download area on the right.

Provider 

Downloads